481 related articles for article (PubMed ID: 33762019)
1. Perspective of mesenchymal transformation in glioblastoma.
Kim Y; Varn FS; Park SH; Yoon BW; Park HR; Lee C; Verhaak RGW; Paek SH
Acta Neuropathol Commun; 2021 Mar; 9(1):50. PubMed ID: 33762019
[TBL] [Abstract][Full Text] [Related]
2. Current Insights into Mesenchymal Signatures in Glioblastoma.
Matsumoto Y; Ichikawa T; Kurozumi K; Date I
Acta Med Okayama; 2022 Oct; 76(5):489-502. PubMed ID: 36352795
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive understanding of glioblastoma molecular phenotypes: classification, characteristics, and transition.
Xu C; Hou P; Li X; Xiao M; Zhang Z; Li Z; Xu J; Liu G; Tan Y; Fang C
Cancer Biol Med; 2024 May; 21(5):363-81. PubMed ID: 38712813
[TBL] [Abstract][Full Text] [Related]
4. Identification of Key Pathways and Genes in the Orai2 Mediated Classical and Mesenchymal Subtype of Glioblastoma by Bioinformatic Analyses.
Yuan F; Yi L; Hai L; Wang Y; Yang Y; Li T; Tong L; Ma H; Liu P; Ming H; Ren B; Yu S; Lin Y; Yang X
Dis Markers; 2019; 2019():7049294. PubMed ID: 31772693
[TBL] [Abstract][Full Text] [Related]
5. Proneural-Mesenchymal Transition: Phenotypic Plasticity to Acquire Multitherapy Resistance in Glioblastoma.
Fedele M; Cerchia L; Pegoraro S; Sgarra R; Manfioletti G
Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31167470
[TBL] [Abstract][Full Text] [Related]
6. Annexin A2-STAT3-Oncostatin M receptor axis drives phenotypic and mesenchymal changes in glioblastoma.
Matsumoto Y; Ichikawa T; Kurozumi K; Otani Y; Fujimura A; Fujii K; Tomita Y; Hattori Y; Uneda A; Tsuboi N; Kaneda K; Makino K; Date I
Acta Neuropathol Commun; 2020 Apr; 8(1):42. PubMed ID: 32248843
[TBL] [Abstract][Full Text] [Related]
7. New insights for precision treatment of glioblastoma from analysis of single-cell lncRNA expression.
Meng Q; Zhang Y; Li G; Li Y; Xie H; Chen X
J Cancer Res Clin Oncol; 2021 Jul; 147(7):1881-1895. PubMed ID: 33693962
[TBL] [Abstract][Full Text] [Related]
8. Nuclear Respiratory Factor 1 (NRF1) Transcriptional Activity-Driven Gene Signature Association with Severity of Astrocytoma and Poor Prognosis of Glioblastoma.
Bhawe K; Felty Q; Yoo C; Ehtesham NZ; Hasnain SE; Singh VP; Mohapatra I; Roy D
Mol Neurobiol; 2020 Sep; 57(9):3827-3845. PubMed ID: 32594352
[TBL] [Abstract][Full Text] [Related]
9. miR-504 suppresses mesenchymal phenotype of glioblastoma by directly targeting the FZD7-mediated Wnt-β-catenin pathway.
Liu Q; Guan Y; Li Z; Wang Y; Liu Y; Cui R; Wang Y
J Exp Clin Cancer Res; 2019 Aug; 38(1):358. PubMed ID: 31419987
[TBL] [Abstract][Full Text] [Related]
10. Investigating the link between molecular subtypes of glioblastoma, epithelial-mesenchymal transition, and CD133 cell surface protein.
Zarkoob H; Taube JH; Singh SK; Mani SA; Kohandel M
PLoS One; 2013; 8(5):e64169. PubMed ID: 23734191
[TBL] [Abstract][Full Text] [Related]
11. Antioxidant network-based signatures cluster glioblastoma into distinct redox-resistant phenotypes.
Yang Y; More S; De Smet F; De Vleeschouwer S; Agostinis P
Front Immunol; 2024; 15():1342977. PubMed ID: 38698847
[TBL] [Abstract][Full Text] [Related]
12. Transcriptional regulatory networks of tumor-associated macrophages that drive malignancy in mesenchymal glioblastoma.
Sa JK; Chang N; Lee HW; Cho HJ; Ceccarelli M; Cerulo L; Yin J; Kim SS; Caruso FP; Lee M; Kim D; Oh YT; Lee Y; Her NG; Min B; Kim HJ; Jeong DE; Kim HM; Kim H; Chung S; Woo HG; Lee J; Kong DS; Seol HJ; Lee JI; Kim J; Park WY; Wang Q; Sulman EP; Heimberger AB; Lim M; Park JB; Iavarone A; Verhaak RGW; Nam DH
Genome Biol; 2020 Aug; 21(1):216. PubMed ID: 32847614
[TBL] [Abstract][Full Text] [Related]
13. miR-181d/MALT1 regulatory axis attenuates mesenchymal phenotype through NF-κB pathways in glioblastoma.
Yang F; Liu X; Liu Y; Liu Y; Zhang C; Wang Z; Jiang T; Wang Y
Cancer Lett; 2017 Jun; 396():1-9. PubMed ID: 28286260
[TBL] [Abstract][Full Text] [Related]
14. Nuclear respiratory factor 1 transcriptomic signatures as prognostic indicators of recurring aggressive mesenchymal glioblastoma and resistance to therapy in White American females.
Bhawe K; Das JK; Yoo C; Felty Q; Gong Z; Deoraj A; Liuzzi JP; Ehtesham NZ; Hasnain SE; Singh VP; Mohapatra I; Komotar RJ; Roy D
J Cancer Res Clin Oncol; 2022 Jul; 148(7):1641-1682. PubMed ID: 35441887
[TBL] [Abstract][Full Text] [Related]
15. Differential gene expression in peritumoral brain zone of glioblastoma: role of SERPINA3 in promoting invasion, stemness and radioresistance of glioma cells and association with poor patient prognosis and recurrence.
Nimbalkar VP; Kruthika BS; Sravya P; Rao S; Sugur HS; Verma BK; Chickabasaviah YT; Arivazhagan A; Kondaiah P; Santosh V
J Neurooncol; 2021 Mar; 152(1):55-65. PubMed ID: 33389566
[TBL] [Abstract][Full Text] [Related]
16. Effect of intra- and inter-tumoral heterogeneity on molecular characteristics of primary IDH-wild type glioblastoma revealed by single-cell analysis.
Xiong Z; Yang Q; Li X
CNS Neurosci Ther; 2020 Sep; 26(9):981-989. PubMed ID: 32488994
[TBL] [Abstract][Full Text] [Related]
17. Silencing LncRNA LOXL1-AS1 attenuates mesenchymal characteristics of glioblastoma via NF-κB pathway.
Wang H; Li L; Yin L
Biochem Biophys Res Commun; 2018 Jun; 500(2):518-524. PubMed ID: 29678575
[TBL] [Abstract][Full Text] [Related]
18. Stem cell signature in glioblastoma: therapeutic development for a moving target.
Nakano I
J Neurosurg; 2015 Feb; 122(2):324-30. PubMed ID: 25397368
[TBL] [Abstract][Full Text] [Related]
19. Prosaposin is a biomarker of mesenchymal glioblastoma and regulates mesenchymal transition through the TGF-β1/Smad signaling pathway.
Jiang Y; Zhou J; Hou D; Luo P; Gao H; Ma Y; Chen YS; Li L; Zou D; Zhang H; Zhang Y; Jing Z
J Pathol; 2019 Sep; 249(1):26-38. PubMed ID: 30953361
[TBL] [Abstract][Full Text] [Related]
20. Glioblastoma Exhibits Inter-Individual Heterogeneity of TSPO and LAT1 Expression in Neoplastic and Parenchymal Cells.
Cai L; Kirchleitner SV; Zhao D; Li M; Tonn JC; Glass R; Kälin RE
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
